Terns Pharmaceuticals (TERN) Competitors $7.63 +0.07 (+0.89%) As of 09:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock TERN vs. TARS, CNTA, DNLI, AGIO, IDYA, IBRX, HRMY, RXRX, OCUL, and IRONShould you be buying Terns Pharmaceuticals stock or one of its competitors? The main competitors of Terns Pharmaceuticals include Tarsus Pharmaceuticals (TARS), Centessa Pharmaceuticals (CNTA), Denali Therapeutics (DNLI), Agios Pharmaceuticals (AGIO), IDEAYA Biosciences (IDYA), ImmunityBio (IBRX), Harmony Biosciences (HRMY), Recursion Pharmaceuticals (RXRX), Ocular Therapeutix (OCUL), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry. Terns Pharmaceuticals vs. Its Competitors Tarsus Pharmaceuticals Centessa Pharmaceuticals Denali Therapeutics Agios Pharmaceuticals IDEAYA Biosciences ImmunityBio Harmony Biosciences Recursion Pharmaceuticals Ocular Therapeutix Disc Medicine Terns Pharmaceuticals (NASDAQ:TERN) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings. Which has more risk and volatility, TERN or TARS? Terns Pharmaceuticals has a beta of -0.04, suggesting that its share price is 104% less volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Which has better valuation and earnings, TERN or TARS? Terns Pharmaceuticals has higher earnings, but lower revenue than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Terns Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTerns PharmaceuticalsN/AN/A-$88.85M-$1.04-7.27Tarsus Pharmaceuticals$182.95M13.31-$115.55M-$2.33-24.76 Do institutionals & insiders have more ownership in TERN or TARS? 98.3% of Terns Pharmaceuticals shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 1.5% of Terns Pharmaceuticals shares are owned by company insiders. Comparatively, 9.0% of Tarsus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor TERN or TARS? In the previous week, Tarsus Pharmaceuticals had 4 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 9 mentions for Tarsus Pharmaceuticals and 5 mentions for Terns Pharmaceuticals. Terns Pharmaceuticals' average media sentiment score of 1.52 beat Tarsus Pharmaceuticals' score of 1.44 indicating that Terns Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Terns Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Tarsus Pharmaceuticals 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer TERN or TARS? Terns Pharmaceuticals currently has a consensus price target of $15.63, indicating a potential upside of 106.63%. Tarsus Pharmaceuticals has a consensus price target of $66.67, indicating a potential upside of 15.58%. Given Terns Pharmaceuticals' higher possible upside, equities research analysts clearly believe Terns Pharmaceuticals is more favorable than Tarsus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Terns Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Tarsus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Is TERN or TARS more profitable? Terns Pharmaceuticals has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -31.13%. Terns Pharmaceuticals' return on equity of -27.35% beat Tarsus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Terns PharmaceuticalsN/A -27.35% -26.18% Tarsus Pharmaceuticals -31.13%-32.36%-21.04% SummaryTerns Pharmaceuticals beats Tarsus Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Terns Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TERN vs. The Competition Export to ExcelMetricTerns PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$661.75M$3.10B$5.77B$9.76BDividend YieldN/A2.28%6.66%4.49%P/E Ratio-7.2720.8683.0526.39Price / SalesN/A391.41527.23108.99Price / CashN/A43.5325.7028.92Price / Book2.178.1011.006.58Net Income-$88.85M-$53.35M$3.28B$265.84M7 Day Performance9.75%-0.29%-0.19%-0.26%1 Month Performance38.24%9.18%8.33%5.82%1 Year Performance4.59%10.11%53.31%22.47% Terns Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TERNTerns Pharmaceuticals4.0342 of 5 stars$7.63+0.9%$15.63+104.9%-0.8%$673.39MN/A-7.4040News CoveragePositive NewsTARSTarsus Pharmaceuticals1.9372 of 5 stars$56.61-1.1%$66.67+17.8%+116.1%$2.42B$182.95M-24.3050News CoveragePositive NewsCNTACentessa Pharmaceuticals2.7447 of 5 stars$17.00-0.1%$28.10+65.3%+27.9%$2.28B$6.85M-9.50200News CoveragePositive NewsAnalyst ForecastDNLIDenali Therapeutics4.3144 of 5 stars$15.57+0.5%$33.62+115.9%-36.8%$2.26B$330.53M-5.56430Positive NewsAGIOAgios Pharmaceuticals4.3579 of 5 stars$37.26-4.0%$56.33+51.2%-14.5%$2.25B$36.50M3.39390News CoveragePositive NewsIDYAIDEAYA Biosciences4.4259 of 5 stars$24.71-1.6%$48.09+94.6%-35.5%$2.20B$7M-6.5280News CoveragePositive NewsIBRXImmunityBio2.6319 of 5 stars$2.25-2.6%$10.75+377.8%-39.7%$2.18B$14.74M-4.69590Positive NewsHRMYHarmony Biosciences4.2841 of 5 stars$37.42-1.2%$51.00+36.3%+3.1%$2.18B$772.53M12.07200Positive NewsRXRXRecursion Pharmaceuticals2.105 of 5 stars$4.83-2.2%$7.00+44.9%-36.0%$2.14B$58.84M-2.71400Positive NewsOCULOcular Therapeutix3.6659 of 5 stars$11.87-3.5%$17.20+44.9%+44.0%$2.14B$63.72M-9.27230Positive NewsIRONDisc Medicine3.2766 of 5 stars$59.41-1.6%$98.30+65.5%+20.8%$2.10BN/A-13.2930News CoveragePositive News Related Companies and Tools Related Companies Tarsus Pharmaceuticals Competitors Centessa Pharmaceuticals Competitors Denali Therapeutics Competitors Agios Pharmaceuticals Competitors IDEAYA Biosciences Competitors ImmunityBio Competitors Harmony Biosciences Competitors Recursion Pharmaceuticals Competitors Ocular Therapeutix Competitors Disc Medicine Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TERN) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Terns Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Terns Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
